Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer. Its product pipeline includes its lead compound, Adva-27 (difluoro-etoposide), a multi-purpose anti-tumor compound in the preclinical stage targeted for various forms of cancer. The company holds a clinical trials agreement with McGill University’s Jewish General Hospital in Montreal, Canada to conduct the research and development of Adva-27a to advance it through the preclinical studies and Phase I clinical trials.

According to the American Cancer Society:

• Approximately 1.5 million new cases of cancer are diagnosed each year in the U.S.
• Over 11 million Americans are living with cancer.
• Virtually all cancers are either aggressive at the onset or become aggressive over time.
• The overall cost of disease treatment is over $126 billion annually.

Aggressive Cancers

• There are two genes which are associated with aggressive forms of cancer: Her2 and Top2
• Herceptin (R)* is an effective treatment for Her2 positive patients.
• There are currently no effective therapies that target Top 2.
• *Herceptin (R)* sales are $1.8 Billion per year.

The Her2 and Top2 Genes

• Her2 gene encodes Human Epidermal Growth Factor Receptor 2
• Top 2 gene encodes Topoisomerase II, an enzyme that unwinds DNA and is required for cell proliferation.
• Her2 and Top2 are located on Chromosome 17 near the BRCA1 gene at 17q21-q22.
• Top2 is often co-amplified in aggressive cancers.
• As many as 10 copies of the Top2 gene have been found in Multi-Drug Resistant Breast Cancer cells.

Inhibition of the Top2 Enzyme

• Inhibition of Topoisomerase II activity (Top2) is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.

Our Proprietary Technology

Many therapeutically important compounds contain diester bonds that link different parts of the molecule together. Diester bonds are naturally unstable often leading to suboptimal performance when the molecule is administered to patients. Diester bonds have specific electrostatic properties and three-dimensional structure that cannot be easily mimicked by other bonds. Chemical structures that do not mimic the diester bond correctly invariably render the compound biologically inactive. In collaboration with Institut National des Sciences Appliquées de Rouen in France (“INSA”), our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere. An isostere is a different chemical structure that mimics the properties of the original. In the body, Carbon-Difluoride compounds are resistant to metabolic degradation but are recognized similarly to the diester containing compounds (see Figure below). This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.

This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. Our in vitro studies have shown that Adva-27a is very effective at killing a variety of cancer types including Multi-Drug Resistant Breast Cancer.

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697.

Partnerships

In June 2011, Sunshine Biopharma entered into a Clinical Trials Agreement with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct the necessary research and development to advance Sunshine’s lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials for Top2 Positive Cancers including small-cell lung cancer.

In January 2011, Sunshine Biopharma entered into a collaboration agreement with Binghamton University (Binghamton, NY) to begin conducting the necessary research and development to advance Sunshine’s lead compound, Adva-27a through various stages of preclinical development and Phase I clinical trials for breast cancer and prostate cancer.

The Company is planning to expand its product line through acquisitions and/or in-licensing as well as in-house research & development.